tradingkey.logo

Cspc Pharmaceutical Says SYH2056 Tablets Obtains Clinical Trial Approval In U.S.

ReutersDec 3, 2025 3:16 PM

- CSPC Pharmaceutical Group Ltd 1093.HK:

  • A SELECTIVE 5-HT2A RECEPTOR AGONIST (SYH2056 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN U.S.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI